ERCC5 Genotype

Every day, the DNA inside your cells takes damage from sunlight, chemicals, and the ordinary work of staying alive. Your body keeps a small toolkit of repair proteins that find these flaws and cut them out. The gene tested here holds the blueprint for one of those cutting tools.

For most people, this is a research-grade genetic marker, not a test that changes what you do next week. In rare families it points to a serious inherited disorder that makes skin dangerously sensitive to the sun, and in cancer research it keeps surfacing as a possible clue to risk and to how well chemotherapy works.

What ERCC5 Actually Is

ERCC5 (Excision Repair Cross-Complementation group 5) is a gene, not a protein you can measure floating in blood. It carries the instructions for a repair protein called XPG (xeroderma pigmentosum group G), which acts like molecular scissors. When your cells spot a bulky flaw in a strand of DNA, XPG makes one of the two precise cuts needed to remove the damaged stretch, snipping on the far side of the damage while a partner protein makes the cut on the near side, so the whole stretch can be pulled out and rebuilt cleanly.

This whole process is a cleanup route your cells use to fix damage from ultraviolet light, chemical pollutants, and platinum chemotherapy drugs, and scientists call it nucleotide excision repair. XPG does more than this cleanup: it also helps cells read their genes normally and lends a hand in several other kinds of DNA repair, including mending broken strands. A genotype test reads which inherited version of ERCC5 you carry, and that version is set at conception and stays the same your whole life.

The Rare Inherited Disorders

When both copies of ERCC5 carry damaging mutations, the repair scissors stop working. This can cause xeroderma pigmentosum, an inherited condition in which skin cannot repair sun damage and skin cancers appear extremely early, sometimes in childhood. The same gene can also produce Cockayne syndrome, a UV-sensitive syndrome, or a severe combined picture with neurological problems. Studies of cells from affected people confirm the defect is specifically in repairing ultraviolet damage.

These disorders are very rare. In western Europe, xeroderma pigmentosum occurs in about 2.3 per million births, a figure that includes immigrant families; among long-established European families the rate is lower, closer to 0.9 per million. That rarity is why ERCC5 is not a routine screening gene for the general public, and why its clearest medical value is confirming a diagnosis in someone who already has worrying symptoms.

Cancer Risk: A Mixed and Context-Dependent Picture

The far more common versions of ERCC5 are tiny single-letter differences called single-nucleotide polymorphisms (SNPs). Researchers have chased these for years to see whether they nudge cancer risk. The honest summary is that the signal is inconsistent.

The most studied variant is rs17655 (also called Asp1104His). An early pooled analysis of 44 studies, covering 23,490 people who had cancer and 27,168 who did not, found no overall link between this variant and cancer risk, and no effect on how much ERCC5 the gene produced. A larger, more recent pooling of 60 studies (about 27,000 people with cancer and 30,500 without) did detect a small overall increase in cancer risk, on the order of 7 percent higher for carriers, concentrated in gastric and colorectal cancer. Either way the effect is modest, and individual studies in specific cancers still report a mix of higher, lower, and no risk.

Source: Joo et al. 2015 (cervical); Chang et al. 2008 (lung); Zhu et al. 2012 (esophageal).

What this means for you: a single ERCC5 variant is not a verdict. The same change that appears to raise risk in one cancer and one population can look protective or neutral in another. Any result has to be read against your specific ancestry and cancer type, not treated as a global risk score.

Why the Same Gene Points Different Directions

It can feel contradictory that one gene appears to raise cervical cancer risk, appears protective against esophageal cancer, and shows only a small signal overall. The resolution is that ERCC5 is not a simple good-number, bad-number marker. How much DNA repair capacity matters depends on the specific type of damage a tissue faces, the local environment, and other genes. A repair tendency that matters for sun-driven or virus-driven cancers may be irrelevant elsewhere, so the meaning of a result is tied to context rather than to one universal direction.

Prognosis and Chemotherapy Response

A second research thread asks whether ERCC5 variants predict how cancer behaves once diagnosed, especially with platinum chemotherapy and radiation, which both work by damaging tumor DNA. The idea is that stronger repair could help a tumor survive treatment. In oral squamous cell carcinoma treated with combined chemotherapy and radiation, men carrying two copies of the rs17655 C version had worse disease-free survival (the time before cancer returns), and carrying risk versions of both ERCC5 and a partner gene raised recurrence risk to about 2.6 times.

In colorectal cancer, one ERCC5 variant known as His46His was tied to shorter disease-free survival in two separate patient groups, which is stronger evidence than most because it repeated. In esophageal cancer treated with platinum, two variants each tracked with poorer survival, and risk climbed as unfavorable versions stacked up.

The chemotherapy-response story is genuinely split. In advanced colorectal cancer, two ERCC5 promoter variants predicted better response to the platinum drug oxaliplatin, with response rates around 73 to 75 percent for the favorable genotypes, and an unfavorable combination raised the odds of not responding to about 2.7 times. But in non-small-cell lung and ovarian cancer, other ERCC5 variants showed no effect on response or survival at all. This is why no guideline currently uses ERCC5 genotype to choose chemotherapy.

A Result You Only Need Once

Because the version of ERCC5 you carry is set at conception and never changes, this is a one-time test. There is no trend to track and no reason to repeat it, unless a lab needs to confirm an unexpected finding using a second method. Its value is not in the reading itself but in how you fold it into decisions over the years.

If you do carry a notable variant, the thing worth tracking over time is not ERCC5 again but the outcomes it may bear on. That means keeping up with age-appropriate cancer screening and, for anyone with sun-sensitivity features, regular skin checks.

What to Do With an Unexpected Result

A single ERCC5 result rarely stands alone. If a genotype panel flags a variant, the sensible next steps depend on the pattern around it. A rare damaging variant found alongside real symptoms of sun sensitivity, early skin cancers, or unexplained neurological problems warrants referral to a clinical geneticist and confirmatory testing, ideally with a broader panel that covers the other repair genes behind overlapping syndromes.

A common SNP found in an otherwise healthy adult is a different situation and usually changes little on its own. Because ERCC5 sits inside a network of repair genes, researchers rarely interpret it in isolation, pairing it with related markers such as ERCC1 and ERCC2 when studying treatment response. If your reason for testing is cancer risk, the practical move is to combine any result with proven screening tools and a conversation with a physician or genetic counselor, rather than acting on the genotype by itself.

When a Genetic Result Can Mislead You

• Panel coverage: the test only detects the specific variants it is designed to read, so a result that finds nothing does not rule out other rare changes in ERCC5 the panel was not built to catch.
• Ancestry matters: many ERCC5 variants are common in one population and rare in another, and a variant that carried risk in a Chinese or Korean study may mean something different in people of European or African ancestry.
• Uncertain variants: a genotype panel can flag a change whose meaning is simply unknown, which is not the same as a known harmful result.
• Germline versus tumor: these tests assume they are reading the DNA you were born with, so contamination from a tumor sample can produce misleading calls.

Consumer genetic reports may list the same ERCC5 positions, but their accuracy and interpretation can differ from a clinical-grade test, so an unexpected consumer result is worth confirming before you act on it.